Skip to main content
Top
Published in: Critical Care 1/2011

Open Access 01-02-2011 | Poster presentation

Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males

Authors: Y Okubo, N Aikawa, M Lynn, DP Rossignol, YN Wong, E Schuck, Y Kitahara, T Nakano, O Sivak, KM Wasan, C Nagy

Published in: Critical Care | Special Issue 1/2011

Login to get access

Excerpt

Activation of TLR4 signaling by endotoxin is believed to be a primary mediator of sepsis and septic shock, via excessive production of cytokines and proinflammatory mediators [1]. Eritoran tetrasodium (hereafter eritoran), a synthetic analog of the endotoxin constituent lipid A, binds to the TLR4/MD-2 complex and thereby blocks the interaction of endotoxin with TLR4 [2]. Eritoran is being investigated for the treatment of severe sepsis [3]. We report results of a study conducted to assess the single-dose safety and tolerability, as well as pharmacokinetics and pharmacodynamics, of eritoran infusion in Japanese and Caucasian healthy adult males. …
Metadata
Title
Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
Authors
Y Okubo
N Aikawa
M Lynn
DP Rossignol
YN Wong
E Schuck
Y Kitahara
T Nakano
O Sivak
KM Wasan
C Nagy
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9685

Other articles of this Special Issue 1/2011

Critical Care 1/2011 Go to the issue